RT Journal Article
SR Electronic
T1 Cardiovascular vulnerability predicts hospitalisation in primary care clinically suspected and confirmed COVID-19 patients: a model development and validation study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.12.21257075
DO 10.1101/2021.05.12.21257075
A1 van Royen, Florien S.
A1 Joosten, Linda P.T.
A1 van Smeden, Maarten
A1 Rutten, Frans H.
A1 Geersing, Geert-Jan
A1 van Doorn, Sander
YR 2021
UL http://medrxiv.org/content/early/2021/05/14/2021.05.12.21257075.abstract
AB Introduction Cardiovascular disease and diabetes have shown to be predictive of clinical deterioration towards critical illness or death in the hospitalised COVID-19 patient population. The aim of this study was to determine the incremental value of cardiovascular vulnerability - defined by the number of cardiovascular diseases and/or diabetes - in predicting the risk of escalation of care towards hospital referral in primary care patients with clinically suspected or confirmed COVID-19.Methods Data were retrospectively collected from three large Dutch primary care registries with routine care data of ±850,000 people. A prognostic prediction model was developed in two databases to assess the incremental value of cardiovascular vulnerability. Data from the ‘first wave’ of COVID-19 infections in the Netherlands (March 1 2020 to June 1 2020) was used for derivation. A multivariable logistic regression model was fitted to predict hospital referral within 90 days follow-up after first consultation in consecutive adult patients seen in primary care for COVID-19 symptoms. Age, sex, the interaction between age and sex, and the number of underlying cardiovascular diseases and/or diabetes (0, 1, or ≥2) were pre-specified as predictors prior to the analyses. The model was (i) compared to a simpler model without the predictor number of cardiovascular diseases and/or diabetes and (ii) externally validated in COVID-19 confirmed patients during the ‘second wave’ (June 1 2020 to April 15 2021) in all three databases.Results There were 5,475 patients included for model development and 6.8% had the primary outcome hospital referral. The model with number of cardiovascular diseases included as a predictor performed better than a model without this predictor (likelihood ratio test p<0.001). Older male patients with multiple cardiovascular diseases and/or diabetes had the highest predicted risk of hospital referral, reaching risks above 15-20% in these patients. The model was externally validated in a population of 16,693 COVID-19 patients. The observed risk was lower in this temporal validation cohort (4.7% versus 6.8%). The temporally validated c-statistic was 0.747 (95%CI 0.729-0.764) and the model showed good calibration.Conclusion In this general population study, risk of clinical deterioration after suspected or confirmed COVID-19 was on average 5.1% in the development and validation cohorts combined. This risk increased with age and was higher in males compared to females. Importantly, patients with concurrent cardiovascular disease and/or diabetes had higher predicted risks. Identifying those at risk for hospital referral could have clinical implications for COVID-19 early disease management in primary care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is funded by the Dutch Heart Foundation (grant number 2020T063). The Dutch Heart Foundation had no role in the design of the study and in writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The need for formal ethical reviewing was waived by the local medical research ethics committee of the University Medical Center Utrecht, the Netherlands as the research did not require direct patient or physician involvement.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used for this study are available from the Dutch routine primary care registries JGPN, ANH and AHA. Restrictions apply to the availability of these data, which are used under license for the current study, and so are not publicly available. Data will however be available from the authors upon reasonable request and with permission of the individual registries.